Title Izražaj vaskularnog endotelnog čimbenika rasta i receptora čimbenika rasta fibroblasta 1 i 2 u karcinomu bubrega
Title (english) The expression of vascular endothelial growth factor and fibroblast growth factor receptors 1 and 2 in renal cell carcinoma
Author Iva Ćorluka
Mentor Katarina Vukojević (mentor)
Committee member Natalija Filipović (predsjednik povjerenstva)
Committee member Snježana Mardešić (član povjerenstva)
Committee member Darko Kero (član povjerenstva)
Granter University of Split School of Medicine (Department of Anatomy, Histology and Embryology) Split
Defense date and country 2020, Croatia
Scientific / art field, discipline and subdiscipline BIOMEDICINE AND HEALTHCARE Basic Medical Sciences Cytology, Histology and Embryology
Abstract Uvod: Karcinom bubrežnih stanica (RCC) najčešći je karcinom bubrega s
kontinuiranim porastom incidencije i smrtnosti u svijetu. Stoga su napori brojnih istraživačkih skupina usmjereni na otkrivanje značajnih dijagnostičkih, prognostičkih i terapijskih biljega koji bi poboljšali kvalitetu zdravstvene usluge za pacijente oboljele od karcinoma bubrežnih stanica.
Ciljevi: Ciljevi našeg istraživanja bili su utvrđivanje izražaja VEGF, FGFR1 i FGFR2 biljega u različitim stadijima karcinoma bubrežnih stanica u odnosu na izražaj u normalnom tkivu te utvrđivanje kolokalizacije VEGF-a s FGFR1 i FGFR2 u karcinomu bubrega s obzirom na patohistološki stupanj tumora.
Materijali i metode: Istraživanje smo proveli na uzorcima tumorskog tkiva i tkiva
zdravog ruba bubrega, uzetim od ispitanika kojima je dijagnosticiran karcinom bubrega niskog (5 uzoraka) i visokog (5 uzoraka) stupnja. Provedeno je dvostruko
imunofluorescencijsko bojenje tkivnih rezova karcinoma bubrega i kontrola na kombinaciju VEGF-a s FGFR1 i FGFR2. Postotak pozitivnih stanica izračunali smo na deset reprezentativnih polja iz svakog reza i izrazili kao srednju vrijednost ± SD, a u odnosu između skupina (niski i visoki stadij te kontrolna skupina). Za analizu podataka koristili smo Kruskal-Wallis i Dunn posthoc test.
Rezultati: Rezultati našeg istraživanja pokazali su pozitivan imunohistokemijski
izražaj VEGF, FGFR1 i FGFR2 u tkivu karcinoma bubrega niskog i visokog stupnja, kao i u normalnom bubrežnom tkivu. Ustanovljena je povremena kolokalizacija FGFR1 i VEGF u normalnom bubrežnom tkivu te kolokalizacija FGFR1 i FGFR2 s VEGF kod karcinoma bubrega niskog i visokog stupnja. U normalnom bubrežnom tkivu, FGFR1, FGFR2 i VEGF pokazali su blagu reaktivnost. U tkivu karcinoma bubrega niskog stupnja FGFR1 je pokazao umjerenu reaktivnost, dok su FGFR2 i VEGF pokazali blagu reaktivnost. U tkivu karcinoma bubrega visokog stupnja, svi biljezi su pokazali umjerenu reaktivnost. Utvrđena je kolokalizacija VEGF - a s FGFR1 i FGFR2 u karcinomu bubrega niskog i visokog stupnja.
Zaključak: Temeljem rezultata utvrđen je izražaj i kolokalizacija VEGF, FGFR1 i
FGFR2 biljega u različitim stadijima karcinoma bubrežnih stanica i u normalnom bubrežnom tkivu. Navedeni rezultati doprinose boljem razumijevanju uloge ovih čimbenika u različitim patohistološkim stadijima karcinoma bubrega.
Abstract (english) Introduction: Renal cell carcinoma (RCC) is the most common type of kidney cancer
with a continuous increase in incidence and mortality in the world. Therefore, the efforts of
numerous research groups are focused on the detection of significant diagnostic, prognostic
and therapeutic markers that would improve the quality of health care for patients with renal
cell carcinoma.
Objectives: The aims of our study were to determine the expression of VEGF, FGFR1
and FGFR2 markers in different stages of renal cell carcinoma in regard to the expression in
normal tissue and to determine the colocalization of VEGF with FGFR1 and FGFR2 in renal
cell carcinoma considering the pathohistological tumor grade.
Materials and methods: The study was performed on samples of tumor tissue and
normal renal tissue, taken from respondents diagnosed with low (5 samples) and high grade (5
samples) renal cell carcinoma according to the WHO. Double imunofluorescence staining of
renal cell carcinoma tissue sections was performed and controlled on combination of VEGF
with FGFR1 and FGFR2. The percentage of positive cells was calculated on ten
representative fields from each section and expressed as mean ± SD and in the relationship
between the groups (low and high stage and control group). We used the Kruskal-Wallis and
Dunn posthoc test for data analysis.
Results: The results of our study showed a positive immunohistochemical expression
of VEGF, FGFR1 and FGFR2 in low and high grade renal cell carcinoma tissue, as well as in
normal renal tissue. Occasional colocalization of FGFR1 and VEGF in normal renal tissue
and colocalization of FGFR1 and FGFR2 with VEGF in low and high grade renal carcinoma,
was established. In normal renal tissue, FGFR1, FGFR2 and VEGF showed mild reactivity. In
low grade renal cell carcinoma tissue, FGFR1 showed moderate reactivity, while FGFR2 and
VEGF showed mild reactivity. In high grade renal cell carcinoma tissue, all markers showed moderate reactivity. The colocalization of VEGF with FGFR1 and FGFR2 in low and high
grade renal carcinoma, was determined.
Conclusion: Based on the results, the expression and colocalization of VEGF, FGFR1
and FGFR2 markers in different stages of renal cell carcinoma and in normal renal tissue,
were determined. These results contribute to a better understanding of the role of these factors
in different pathohistological stages of renal cell carcinoma.
Keywords
Novotvorine bubrega
Adenokarcinom
Čimbenici rasta vaskularnog endotela
Receptori čimbenika rasta fibroblasta
Imunohistokemija
Keywords (english)
Kidney Neoplasms
Adenocarcinoma
Vascular Endothelial Growth Factors
Receptors Fibroblast Growth Factor
Immunohistochemistry
Language croatian
URN:NBN urn:nbn:hr:171:925999
Study programme Title: Dental Medicine Study programme type: university Study level: integrated undergraduate and graduate Academic / professional title: doktor/doktorica dentalne medicine (doktor/doktorica dentalne medicine)
Type of resource Text
File origin Born digital
Access conditions Open access
Terms of use
Created on 2020-11-17 12:05:53